Navigating the spatial biology landscape can feel like standing in front of a massive soundboard, trying to balance dozens of sliders at once. Every platform promises single-cell or near single-cell resolution,
but each hits that benchmark through fundamentally different engineering.
In genomic research, mapping structural chromatin accessibility (scATAC-Seq) or sequencing cellular transcripts (scRNA-Seq) from separate cell aliquots provides an informative, yet fractured, perspective.
When designing a single-cell transcriptomics study, selecting the appropriate assay chemistry determines how you collect samples, manage budgets, and structure your data.
Choosing the right single-cell technology is one of the most critical decisions in modern genomic experimental design. Selecting an mismatched platform doesn’t just inflate sequencing costs—it can actively bias your data by destroying fragile cell types, failing to capture rare cell variants, or missing critical splice isoforms.
Proteomics has never offered more ways to measure the proteome, and that abundance of choice is exactly what makes method selection difficult. Mass spectrometry, targeted assays, and affinity-based platforms each measure proteins in fundamentally different ways, and no single approach is best for every question.
Multiomics research has fundamentally changed what it means to outsource NGS. It is no longer sufficient to find a vendor that can only sequence a library. Modern programs integrating RNA-seq, single-cell profiling, spatial transcriptomics, epigenomics, and long-read sequencing demand a partner with platform depth, rigorous quality standards, and the operational efficiency to keep budgets and timelines intact. Choosing the wrong partner does not just slow you down—it can compromise the integrity of your entire project.
The road from protein biomarker discovery to clinical utility is rarely straight. Researchers routinely identify candidate proteins in discovery-phase experiments, only to watch those signals fail to replicate under the rigorous quantitative conditions required for translational validation.
The advent of single-cell RNA sequencing (scRNA-seq) has fundamentally redefined transcriptomic profiling by resolving transcriptional states at single cell resolution.
Unlike bulk RNA-seq, which obscures cell-to-cell variability through population averaging, scRNA-seq captures the heterogeneity, rare populations, and transitional states that underlie developmental trajectories and pathological processes. Its adoption has been rapid across immunology, oncology, neuroscience, and developmental biology, where cellular diversity is mechanistically linked to function and disease.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
